[Laboratory and clinical study of cefamandole by intravenous injection in the pediatric field (author's transl)]. 1979

S Nakazawa, and H Satoh, and K Niino, and S Nakazawa, and H Suzuki, and A Iwasaki, and H Chikaoka, and S Oka, and Y Hirama, and A Narita

Cefamandole sodium (CMD) was intravenously administered and following laboratoric and clinical results were obtained. (1) The peak blood concentration was 32 approximately 44 micrograms/ml when the drip infusion was finished. At 1 hour after the end of the drip infusion the blood concentration was 7.6 approximately 8.1 micrograms/ml. Half life was approximately 0.64 hours. (2) Urinary recovery rate was 84.5 approximately 95% in active state within 6 hours. (3) Penetration of cerebrospinal fluid was found in 2 cases. (4) In most of 170 strains of Streptococcus haemolyticus MICs of cefamandole were 0.05 microgram/ml. They were less susceptible to cefazoline, cefmetazole and ceftezole. (5) CMD was administered to 35 pediatric patients (upper or lower RTI, lymphadenitis, enteritis or UTI) at 100 mg/kg/day for 3 approximately 9 days, the efficacy rate was 97.1%. (6) Side effect: Rash occurred in one case, and eosinophilia was observed in 4 cases. No abnormal finding of renal and liver function was observed.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D008297 Male Males
D012141 Respiratory Tract Infections Invasion of the host RESPIRATORY SYSTEM by microorganisms, usually leading to pathological processes or diseases. Respiratory System Infections,Upper Respiratory Tract Infection,Upper Respiratory Tract Infections,Infections, Respiratory,Infections, Respiratory Tract,Infections, Upper Respiratory,Infections, Upper Respiratory Tract,Respiratory Infections,Upper Respiratory Infections,Infection, Respiratory System,Infection, Respiratory Tract,Respiratory Infection, Upper,Respiratory System Infection,Respiratory Tract Infection
D002435 Cefamandole Semisynthetic wide-spectrum cephalosporin with prolonged action, probably due to beta-lactamase resistance. It is used also as the nafate. Cephamandole,Compound 83405
D002511 Cephalosporins A group of broad-spectrum antibiotics first isolated from the Mediterranean fungus ACREMONIUM. They contain the beta-lactam moiety thia-azabicyclo-octenecarboxylic acid also called 7-aminocephalosporanic acid. Antibiotics, Cephalosporin,Cephalosporanic Acid,Cephalosporin,Cephalosporin Antibiotic,Cephalosporanic Acids,Acid, Cephalosporanic,Acids, Cephalosporanic,Antibiotic, Cephalosporin,Cephalosporin Antibiotics
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D005260 Female Females

Related Publications

S Nakazawa, and H Satoh, and K Niino, and S Nakazawa, and H Suzuki, and A Iwasaki, and H Chikaoka, and S Oka, and Y Hirama, and A Narita
November 1979, The Japanese journal of antibiotics,
S Nakazawa, and H Satoh, and K Niino, and S Nakazawa, and H Suzuki, and A Iwasaki, and H Chikaoka, and S Oka, and Y Hirama, and A Narita
April 1980, The Japanese journal of antibiotics,
S Nakazawa, and H Satoh, and K Niino, and S Nakazawa, and H Suzuki, and A Iwasaki, and H Chikaoka, and S Oka, and Y Hirama, and A Narita
September 1979, The Japanese journal of antibiotics,
S Nakazawa, and H Satoh, and K Niino, and S Nakazawa, and H Suzuki, and A Iwasaki, and H Chikaoka, and S Oka, and Y Hirama, and A Narita
September 1979, The Japanese journal of antibiotics,
S Nakazawa, and H Satoh, and K Niino, and S Nakazawa, and H Suzuki, and A Iwasaki, and H Chikaoka, and S Oka, and Y Hirama, and A Narita
October 1979, The Japanese journal of antibiotics,
S Nakazawa, and H Satoh, and K Niino, and S Nakazawa, and H Suzuki, and A Iwasaki, and H Chikaoka, and S Oka, and Y Hirama, and A Narita
December 1981, The Japanese journal of antibiotics,
S Nakazawa, and H Satoh, and K Niino, and S Nakazawa, and H Suzuki, and A Iwasaki, and H Chikaoka, and S Oka, and Y Hirama, and A Narita
September 1980, The Japanese journal of antibiotics,
S Nakazawa, and H Satoh, and K Niino, and S Nakazawa, and H Suzuki, and A Iwasaki, and H Chikaoka, and S Oka, and Y Hirama, and A Narita
March 1981, The Japanese journal of antibiotics,
S Nakazawa, and H Satoh, and K Niino, and S Nakazawa, and H Suzuki, and A Iwasaki, and H Chikaoka, and S Oka, and Y Hirama, and A Narita
March 1981, The Japanese journal of antibiotics,
S Nakazawa, and H Satoh, and K Niino, and S Nakazawa, and H Suzuki, and A Iwasaki, and H Chikaoka, and S Oka, and Y Hirama, and A Narita
April 1976, The Japanese journal of antibiotics,
Copied contents to your clipboard!